Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy for hepatocellular carcinoma
Zongyi Yin, Xiaowu Li
Cancer Letters (2019) Vol. 470, pp. 8-17
Closed Access | Times Cited: 212

Showing 1-25 of 212 citing articles:

Pyroptosis: mechanisms and diseases
Pian Yu, Xu Zhang, Nian Liu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1505
Recent advances in systemic therapy for hepatocellular carcinoma
Huajun Zhang, Wuyang Zhang, Longying Jiang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 160
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
Zhuoyan Liu, Xuan Liu, Jiaxin Liang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 110
FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2
Meng Xie, Zhuoying Lin, Xiaoyu Ji, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 109-125
Open Access | Times Cited: 86
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation
Neda Yahoo, Michael Dudek, Percy A. Knolle, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 538-551
Open Access | Times Cited: 61
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
Deepa S. Mandlik, Satish K. Mandlik, Heena B Choudhary
World Journal of Gastroenterology (2023) Vol. 29, Iss. 6, pp. 1054-1075
Open Access | Times Cited: 58
The role of RNA methylation in tumor immunity and its potential in immunotherapy
Yan Li, Haoer Jin, Qingling Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 24
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 532-532
Open Access | Times Cited: 79
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine (2022) Vol. 12, Iss. 11, pp. 1788-1788
Open Access | Times Cited: 55
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
Yue Chen, Haoyue Hu, Xianglei Yuan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 44
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Yinjie Fan, Hang Xue, Hua‐chuan Zheng
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 233-263
Open Access | Times Cited: 43
pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors
Rui Sun, Wen Ma, Mingjian Ling, et al.
Journal of Controlled Release (2022) Vol. 350, pp. 525-537
Closed Access | Times Cited: 40
Hepatocellular Carcinoma Cell-Derived Exosomal miR-21-5p Induces Macrophage M2 Polarization by Targeting RhoB
Haiyang Yu, Jing Pan, Siyue Zheng, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4593-4593
Open Access | Times Cited: 32
Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
Xue-Qin Gong, Ning Liu, Yun-Yun Tao, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 22
The interaction between intratumoral bacteria and metabolic distortion in hepatocellular carcinoma
Chen Xue, Xinyu Gu, Qingmiao Shi, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: a step-toward personalized medicine
Nadia Μ. Hamdy, Emad B. Basalious, Mona G. El-Sisi, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 11, pp. 1943-1961
Closed Access | Times Cited: 10
Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma
Xuanlong Du, Yewei Zhang
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 61
MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells
Ningning Liu, Ching-Wen Chang, Clifford J. Steer, et al.
Gastroenterology (2021) Vol. 162, Iss. 2, pp. 575-589
Closed Access | Times Cited: 52
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Dexi Zhou, Jiajie Luan, Cheng Huang, et al.
Gut and Liver (2020) Vol. 15, Iss. 4, pp. 500-516
Open Access | Times Cited: 50
Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness
Mathilde Cadoux, Stefano Caruso, Sandrine Pham, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1386-1397
Open Access | Times Cited: 49
Autophagy, an accomplice or antagonist of drug resistance in HCC?
Yafei Wu, Jigang Zhang, Qin Li
Cell Death and Disease (2021) Vol. 12, Iss. 3
Open Access | Times Cited: 48
Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma
Lei Guo, Hongbo Li, Tianli Fan, et al.
Life Sciences (2021) Vol. 279, pp. 119359-119359
Closed Access | Times Cited: 40
Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma
Xiaofeng Kang, Yan Huo, Songhao Jia, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 34
Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations
Anthony Bejjani, Richard S. Finn
Journal of Clinical Oncology (2022) Vol. 40, Iss. 24, pp. 2763-2773
Closed Access | Times Cited: 29
Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma
Yi‐Wei Xu, Xiaodong Hao, Yidan Ren, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top